CJC-1295 no DAC

from $49.00

CJC-1295 No DAC — Growth Hormone & Endocrine Signaling Research

A synthetic growth hormone-releasing hormone (GHRH) analog studied around the biology of pituitary signaling, growth hormone release, and endocrine communication, with particular interest in the pathways connecting the hypothalamus, pituitary gland, and peripheral tissues.

The compound commonly marketed as “CJC-1295 No DAC” is a short-acting GHRH analog related to modified GRF(1-29). Unlike CJC-1295 with a Drug Affinity Complex (DAC), the no-DAC form does not contain the albumin-binding modification designed to substantially extend circulation time. Research involving GHRH analogs explores growth hormone pulsatility, pituitary somatotroph signaling, GH/IGF-1 physiology, and neuroendocrine regulation. CJC-1295 No DAC is not an FDA-approved medication.

Research Focus: GHRH Signaling • Growth Hormone Physiology • Pituitary Function • GH/IGF-1 Axis • Hormonal Pulsatility • Neuroendocrine Communication • Endocrine Research

A short-acting GHRH-related research peptide for those interested in the science of growth hormone signaling, pituitary communication, hormonal pulsatility, and the endocrine pathways involved in the GH/IGF-1 axis.

Educational Disclaimer

This information is provided for educational purposes regarding the biological and scientific research associated with the ingredients listed. It is not intended to diagnose, treat, cure, or prevent disease or to provide individualized medical advice.

MG:

CJC-1295 No DAC — Growth Hormone & Endocrine Signaling Research

A synthetic growth hormone-releasing hormone (GHRH) analog studied around the biology of pituitary signaling, growth hormone release, and endocrine communication, with particular interest in the pathways connecting the hypothalamus, pituitary gland, and peripheral tissues.

The compound commonly marketed as “CJC-1295 No DAC” is a short-acting GHRH analog related to modified GRF(1-29). Unlike CJC-1295 with a Drug Affinity Complex (DAC), the no-DAC form does not contain the albumin-binding modification designed to substantially extend circulation time. Research involving GHRH analogs explores growth hormone pulsatility, pituitary somatotroph signaling, GH/IGF-1 physiology, and neuroendocrine regulation. CJC-1295 No DAC is not an FDA-approved medication.

Research Focus: GHRH Signaling • Growth Hormone Physiology • Pituitary Function • GH/IGF-1 Axis • Hormonal Pulsatility • Neuroendocrine Communication • Endocrine Research

A short-acting GHRH-related research peptide for those interested in the science of growth hormone signaling, pituitary communication, hormonal pulsatility, and the endocrine pathways involved in the GH/IGF-1 axis.

Educational Disclaimer

This information is provided for educational purposes regarding the biological and scientific research associated with the ingredients listed. It is not intended to diagnose, treat, cure, or prevent disease or to provide individualized medical advice.

These products are designated solely for research purposes only and is not intended for human consumption. These products are expressly tailored for laboratory inquiries, comprising both in vitro assessments and in vivo animal experiments, to be conducted exclusively by trained professionals. Compliance with all relevant regulations and directives is essential in the handling and deployment of these items. By acquiring these goods, you commit to their utilization strictly in conformity with prevailing regulations and solely for legitimate research purposes. Any unauthorized or improper usage of these products is explicitly prohibited.